Zie ook het ervaringsverhaal van Bob met niet kleincellige longkanker stadium 4 met atezolizumab.

4 december 2017: klik op de titels voor de studierapporten.

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab

en

PD-L1 Inhibition With Atezolizumab (MPDL3280A) for Solid Tumors

Cancer immunotherapy has become a popular anticancer approach, with the goal of stimulating immune responses against tumor cells. Recent evidence has demonstrated that the use of monoclonal antibodies targeting the programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) checkpoint pathway can result in well-tolerated clinical responses in a wide variety of tumor types. This review summarizes the safety, clinical activity and biomarker data for the anti-PD-L1 antibody, MPDL3280A, from a phase Ia multicenter, dose-escalation and -expansion trial. The data to date suggest that MPDL3280A is most effective in patients with pre-existing immunity suppressed by PD-L1 and reinvigorated upon antibody treatment.

Table 1Summary of Safety of MPDL3280A Across Tumor Types
Tumor TypenaAll-Grade AEs, %bGrade 3/4 AEs, %bData Cutoff
Bladder11 68 57% 4% January 1, 2014
Melanoma12 45 80% 16% January 1, 2014
RCC18 69 80% 3% April 21, 2014
View Table in HTML

Abbreviations: AE, adverse event; RCC, renal cell carcinoma.

aSafety-evaluable population.
bTreatment-related AEs.
Table 2Summary of Efficacy of MPDL3280A Across Tumor Typesa
Tumor TypenbORR, %Dosed by DateData Cutoff
Overall10 175 21% October 1 2012 April 30, 2013
Melanoma12 43 28% July 1 2013 January 1, 2014
NSCLC10 53 23% October 1 2012 April 30, 2013
RCC18 62 15% October 21 2013 April 21, 2014
Other10 23 13% October 1 2012 April 30, 2013
View Table in HTML

Abbreviations: NSCLC, non-small cell lung cancer; ORR, overall response rate; RCC, renal cell carcinoma.

aPer RECIST v1.1. All responses were confirmed except for one patient with NSCLC.
bEfficacy-evaluable population.

Gerelateerde artikelen